AOTMiT: What drugs will the Transparency Council assess next Monday?

The agenda is:

• Preparation of positions on drug evaluation:

Inrebic (fedratinibum) under the drug program: "Treatment of primary myelofibrosis and secondary myelofibrosis in the course of polycythemia vera and essential thrombocythemia (ICD-10 D47.1)",

Kesimpta (ofatumumabum) under the drug program: B.29 "Treatment of Multiple Sclerosis (ICD-10 G35)".

• Preparation of an opinion on reimbursement of drugs containing active substances:

acidum folicum in the indication: rheumatic diseases - in patients treated with methotrexate,

nitrendipinum in the indication: Raynaud's phenomenon associated with systemic sclerosis - first-line treatment,

amlodipine in the indication: Raynaud's phenomenon associated with systemic sclerosis - first-line treatment,

budesonidum in the indication: viral laryngitis in children up to 18 years of age.

Source: AOTMIT